Skip to main content

The Drug Development Paradigm in Oncology Proceedings of a Workshop (2018) / Chapter Skim
Currently Skimming:

Appendix B: Workshop Agenda
Pages 117-122

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 117...
... Schilsky, American Society of Clinical Oncology • Mark Ratain, The University of Chicago • Mace Rothenberg, Pfizer Inc. • Janet Woodcock, Food and Drug Administration • Ellen Sigal, Friends of Cancer Research Panel Discussion 10:00 am Break 117
Read the entire page →
From page 118...
... 118 THE DRUG DEVELOPMENT PARADIGM IN ONCOLOGY 10:15 am Session 2: Case Studies and Lessons Learned from Recent Experiences Moderator: Suzanne Topalian, Johns Hopkins University Anti-PD-1 Immunotherapy • Eric Rubin, Merck BRAF Pathway Inhibitors • Keith Flaherty, Massachusetts General Hospital T790M EGFR Inhibitors •  Jänne, Dana-Farber Cancer Institute Pasi Challenges Resulting from Rapid Regulatory Approvals • Donald Harvey, Emory University Panel Discussion – Session speakers and • Gideon Blumenthal, Food and Drug Administration 12:15 pm Lunch 1:00 pm Session 3: Flexible Drug Development and Decision Making: Accommodating New Insights Moderator: Mace Rothenberg, Pfizer Inc. Understanding Biological Activity to Inform Drug Development • Kenneth Anderson, Dana-Farber Cancer Institute • Wolfgang Weber, Memorial Sloan Kettering Cancer Center Assessing Early Signals of Efficacy to Guide Clinical Development • David Feltquate, Bristol-Myers Squibb • Richard Finn, University of California, Los Angeles, Jonsson Comprehensive Cancer Center Dose-Finding Considerations and Strategies for Novel Combination Development • Steven Piantadosi, Cedars-Sinai Medical Center
Read the entire page →
From page 119...
... Schilsky, American Society of Clinical Oncology December 13, 2016 7:30 am Registration 8:00 am The National Cancer Moonshot Initiative and Seamless Drug Development Moderator: Richard L Schilsky, American Society of Clinical Oncology Blue Ribbon Panel Recommendations • Elizabeth Jaffee, Johns Hopkins University Q&A
Read the entire page →
From page 120...
... Panel Discussion 11:15 am Break 11:30 am Session 6: Stakeholder Perspectives: Goals of the New Paradigm and Priorities for the Path Forward Moderator: Steven Piantadosi, Cedars-Sinai Medical Center • Howard A Burris, III, Sarah Cannon Research Institute • Elizabeth Jaffee, Johns Hopkins University
Read the entire page →
From page 121...
... Schilsky, American Society of Clinical Oncology Planning Committee Chair 1:00 pm Adjourn
Read the entire page →

Key Terms

  • clinical oncology
  • janet woodcock
  • sarah cannon
  • cancer research
  • planning committee

  • committee chair
  • elizabeth jaffee
  • cannon research
  • panel discussion
  • drug administration

  • american society
  • johns hopkins
  • pfizer inc
  • seamless drug
  • hopkins university

  • research institute
  • medical center
  • moonshot initiative
  • cancer moonshot
  • blue ribbon

  • panel recommendations
  • path forward
  • steven piantadosi
  • national cancer
  • mace rothenberg

  • ribbon panel


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.